The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Table 4 Deterioration status from baseline in each examination using reliable change index

Deterioration status	RCT arm		RT arm		p
Deterioration status	Deterioration	No deterioration	Deterioration	No deterioration	p
At 3 months
HVLT-R TR	21	84	19	68	0.76
HVLT-R DR	23	82	32	55	0.02
TMT Part A	22	81	25	63	0.26
TMT Part B	24	79	33	55	0.03
COWA	19	86	28	61	0.03
FACT-L	23	79	24	61	0.45
At 5 months
HVLT-R TR	21	511	33	31	0.008
HVLT-R DR	23	49	35	29	0.007
TMT Part A	18	52	25	37	0.07
TMT Part B	21	49	30	32	0.03
COWA	19	53	32	29	0.002
FACT-L	25	48	36	29	0.01
At 7 months
HVLT-R TR	20	22	19	17	0.65
HVLT-R DR	24	18	17	19	0.38
TMT Part A	23	21	21	15	0.59
TMT Part B	25	19	22	14	0.70
COWA	24	20	20	14	0.71
FACT-L	24	17	21	12	0.66

Abbreviations: HVLT-R TR Hopkins Verbal Learning Test total recall, HVLT-R DR Hopkins Verbal Learning Test delayed recall, TMT Trail-making Test, COWA Controlled Oral Word Association, FACT-L Functional Assessment of Cancer Treatment-Lung

ISSN: 1471-2407